Feedback / Questions
BND-22 - Biond Biologics, Sanofi
https://www.prnewswire.com/news-releases/biond-biologics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-bnd-22-a-novel-immune-checkpoint-inhibitor-targeting-the-ilt2-receptor-301276510.html
Apr 26, 2021
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next